Avillion Signs Co-Development Agreement with Pearl Therapeutics Inc. (part of AstraZeneca) to Conduct Clinical Development of PT027 in Asthma

Avillion has signed a co-development agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of the AstraZeneca Plc group, to advance PT027 through a global clinical development programme for the treatment of asthma.

Please read the full press release here.

TwitterLinkedInEmailPrint